Condition: Ovarian Cancer · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The primary endpoint of the study is the reduction of insulin levels between the two groups. Using the Student's t-test, while maintaining the study power at 95% and the significance level at 5%, a sample of 27+27 patients will allow the identification of differences in terms of Cohen's d equal to 1.
This description comes directly from the study's public registry record.
claudia marchetti · 0630158556 · claudia.marchetti@policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| DH Tumori Femminili | Roma, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07039331